PARIS & BOSTON, October 28, 2021--(BUSINESS WIRE)--Regulatory News:
Mauna Kea Technologies (Euronext: MKEA) (Paris:MKEA) (OTCQX:MKEAY) inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today announced third quarter and first nine months of 2021 sales results for the periods ended September 30, 2021.
First Nine Months of 2021 Sales Summary:
Total sales for the first nine months of 2021 increased €0.9 million, or 23% year-over-year, to €5.1 million
Consumables sales increased €0.4 million, or 23% year-over-year, to €2.3 million
Systems sales increased €0.5 million, or 36% year-over-year, to €2.0 million
Services sales were €0.8 million, unchanged year-over-year
Third Quarter 2021 Sales Summary:
Total sales for the third quarter of 2021 decreased €0.3 million, or 13% year-over-year, to €1.8 million
Consumables sales decreased €0.2 million to €0.7 million
Systems sales decreased €0.1 million to €0.8 million
Services sales were €0.3 million, unchanged year-over-year
"Our third quarter sales results reflect softer-than-expected procedure and adoption trends in our primary commercial markets as a result of the surge in COVID-19 cases associated with the Delta variant," stated Robert L. Gershon, Chief Executive Officer of Mauna Kea Technologies. "Our U.S. customers experienced significant COVID-related business disruption in recent months and capital equipment adoption trends have not progressed at the pace that we expected coming into the year. Consumable demand from U.S. customers has been impacted by lower patient throughput and a shift in procedure prioritization to non-elective procedures in response to the increase in new COVID-19 Delta cases during the quarter. As expected, the pace of recovery in APAC continues to lag the U.S. which impacted demand for consumables and capital equipment from our distribution partner in China. Notably, sales results in EMEA were impressive in light of the continued COVID-related challenges in the region; we were pleased to deliver five new systems to customers in EMEA during the third quarter, the majority of which were a result of our efforts to expand awareness of the utility of Cellvizio in potential new clinical applications within GI. Specifically, new system adoption in EMEA during Q3 was driven by customers that valued Cellvizio’s demonstrated efficacy in the food allergy and pancreatic cyst markets."
Mr. Gershon continued: "Given the slower-than-anticipated recovery in the global capital equipment market to-date and our revised outlook for customer demand in our primary global markets driven by the unexpected rise in COVID-19 cases driven by the Delta variant, we have revised our growth expectations for the full year 2021 period. Importantly, while we are not as far along in the COVID-recovery as previously expected, our fourth quarter sales expectations reflect continued improvement on a sequential basis. Specifically, we expect sales to increase in the range of 18% - 20% on a quarter-over-quarter basis in the fourth quarter, driven primarily by strong execution of our commercial strategy, measured improvement in consumable demand and modest improvement in the capital equipment environment, as compared to the third quarter."
Third Quarter and First Nine Months of 2021 Sales by Category*:
(in € millions) – IFRS
*Numbers may not tie due to rounding
Total sales for the third quarter of 2021 were €1.8 million, down 13% year-over-year. Third quarter sales results were driven by a 20% decrease in consumables sales and a 11% decrease in system sales, compared to the prior year period.
Total sales for the first nine months of 2021 were €5.1 million, up 23% year-over-year. First nine months of 2021 sales results were driven by a 36% increase in sales of systems and a 23% increase in consumables sales, compared to the prior year period.
Third Quarter and First Nine Months of 2021 by Geographic Region*:
(in € millions) – IFRS
EMEA & ROW
*Numbers may not tie due to rounding
The change in total sales for the third quarter of 2021, by geographic region, was driven primarily by a 73% decrease in sales to customers in the Asia-Pacific region and a 16% decrease in sales to customers in the U.S., offset partially by a 69% increase in sales to customers in the EMEA and ROW regions, compared to the prior year period.
The change in total sales for the first nine months of 2021, by geographic region, was driven by a 115% increase in sales to customers in the EMEA and ROW regions and a 6% increase in sales to customers in the U.S., offset partially by a 6% decrease in sales to customers in the Asia-Pacific region, compared to the prior year period.
Third Quarter and First Nine Months of 2021 Units Sales by Type
New Systems Sold
New System Placements
Consumable Probe Shipments
Total shipments of Cellvizio systems decreased 15% year-over-year to 11 in the third quarter of 2021, compared to 13 in the prior year period. Third quarter of 2021 total systems included 3 new system placements to U.S. customers. Consumable probe shipments decreased 32% year-over-year in the third quarter of 2021.
Total Cellvizio System shipments increased 43% year-over-year to 33 in the first nine months of 2021, compared to 23 in the prior year period. Consumable probe shipments increased 30% year-over-year in the first nine months of 2021 driven by stronger procedure trends as compared to the prior year period.
Please note that the 2021 financial calendar is available on the Mauna Kea Technologies website:
About Mauna Kea Technologies
Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients.
For more information, visit www.maunakeatech.com
This press release contains forward-looking statements concerning Mauna Kea Technologies and its activities. All statements other than statements of historical fact included in this press release, including, without limitation, those regarding Mauna Kea Techonologies’ financial condition, business, strategies, plans and objectives of management for future operations are forward-looking statements. Such forward looking statements are based on assumptions that Mauna Kea Technologies considers to be reasonable. However, there can be no assurance that the anticipated events contained in such forward-looking statements will occur. Forward- looking statements are subject to numerous risks and uncertainties, including the risks set forth in Chapter 3 of the 2020 Universal Registration Document of Mauna Kea Technologies registered by the French Financial Markets Authority (Autorité des marchés financiers (AMF)) on June 17, 2021 under number D-21-0566 and the amendment to the 2020 Universal Registration Document filed with the AMF on September 17, 2021, which are both available on the Company's website (www.maunakeatech.com), and risks relating the economic situation, financial markets, and the markets in which Mauna Kea Technologies operates. The forward-looking statements contained in this release are also subject to risks unknown to Mauna Kea Technologies or that Mauna Kea Technologies does not consider material at this time. The realization of all or part of these risks could lead to actual results, financial conditions, performances or achievements by Mauna Kea Technologies that differ significantly from the results, financial conditions, performances or achievements expressed in such forward-looking statements. This press release and the information it contains do not constitute an offer to sell or to subscribe for, or a solicitation of an order to purchase or subscribe for, Mauna Kea Technologies shares in any jurisdiction in which such an offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. The distribution of this document may, in certain jurisdictions, be restricted by local regulations. Persons who come into possession of this document are required to observe all applicable local regulations relating to this document.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211028005837/en/
Mike Piccinino, CFA
Westwicke, an ICR Company
France and Europe
NewCap - Investor Relations
+33 (0)1 44 71 94 94